Remove Bioassay Remove Genomics Remove Research
article thumbnail

Using analytics and bioassays to de-risk your mRNA LNP drug development programme

Pharmaceutical Technology

Another area where we tend to see problems is in encapsulation efficiency,” says Andrew Kondratowicz, Bioassay Team Lead, Precision NanoSystems. The bioassays are the canary in the coal mine of how well your process development is going. Outlook The era of mRNA-based genomic medicines is on the horizon. Where is your payload?

Bioassay 130
article thumbnail

Evaluating methods targeting Protein-Protein Interactions

pharmaphorum

It is a popular method in systems biology, requiring fewer compounds to be screened in bioassays, reducing time and cost. A recent clinical research paper highlights the importance of targeting of PPIs in stem cells of cancer. This innovative method now brings technology closer to developing genome-wide PPI networks.

Protein 126